Fresh analysis reveals that patients who discontinue popular GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who halt traditional lifestyle regimens.
Research printed in a prominent health publication points out that while overweight individuals frequently drop about a fifth of their body weight while on the medication, the mass is regained at an average rate of nearly a kilo each month once they quit.
"People purchasing these medications should be cognizant of the potential of rapid rebound weight gain when the medication concludes," stated researcher Dr. Susan Jebb.
That rate of regain implies a reversion to starting weight within about a year and a half.
Weighing Approaches
The research, which looked at dozens of trials involving over 9,000 of patients, contrasted the outcomes of the injectable medications with other pills.
The team note that individuals who lose weight through dieting typically see a slower creep back—around 0.1 kg a month—post-intervention.
Explaining the Rapid Regain
Nutrition scientists propose the mode of action of the injections is key to understanding the accelerated rebound.
The injections mimic a body's own chemical called GLP-1, which helps regulate appetite.
"Sustained high doses of GLP-1 levels far above than normal may cause the system to produce less of its endogenous GLP-1, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement leads to hunger is uncontrolled, making overeating a significant risk."
An Ongoing Disease?
Health authorities suggest the injections for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Professionals argue that, given the high risk of relapse, the therapy is often ongoing.
This perspective is reinforced by drug manufacturers, who say that the findings "highlight the chronic character of excess weight," comparing it to managing conditions like high blood pressure.
User Experiences
Individuals who have discontinued the medication explain a intense resurgence of cravings.
"I experienced something activating and I was suddenly ravenous," described one woman.
This challenge is worsened if individuals have not established sustainable lifestyle or habit modifications during therapy.
Growing Adoption
Recent estimates show that a significant number of people in the UK have tried these injections in the past year, with desire being substantial.
- Use is more common among women than males.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
In conclusion, researchers stress that while these medications are powerful tools for shedding pounds, they are not a permanent solution and maintained weight loss likely depends on ongoing lifestyle support.
